The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression DOI Creative Commons

Maria-Lorena Mustață,

Mihaela Ionescu,

Lucreţiu Radu

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(24), P. 2887 - 2887

Published: Dec. 23, 2024

Background/Objectives: Psoriasis is a chronic dermatological condition with systemic implications, especially metabolic syndrome (MS). This study evaluated the vicious cycle where obesity and MS exacerbate inflammation that complicates efficacy of psoriasis therapies by examining PASI score over one-year period. Patients were classified into two subgroups: those alone (PSO) both (PSO-MS). Methods: A total 150 patients, half whom also concomitantly presented syndrome, received biologic comprising anti-IL-17, anti-IL-23, anti-TNF-a, or methotrexate, scores assessed at baseline 3, 6, 12 months. Results: All treatments showed significant reductions in PASI; however, patients PSO more marked than PSO-MS group. Anti-IL-17 produced greatest sustained long-term improvements, whereas anti-IL-23 prompt early improvements. Increases BMI leptin concentrations associated modest rate reduction score, underlining impact dysfunction on treatment efficacy. Conclusions: highlights importance managing comorbidities such as psoriasis, interplay between health further therapeutic outcomes.

Language: Английский

Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation DOI Creative Commons
Mislav Radić, Andrej Belančić, Hana Đogaš

et al.

Metabolites, Journal Year: 2025, Volume and Issue: 15(3), P. 206 - 206

Published: March 18, 2025

Psoriatic arthritis (PsA) is a chronic inflammatory disease that extends beyond musculoskeletal and dermatologic involvement to elevate cardiometabolic risk. Emerging evidence highlights the critical role of systemic inflammation in metabolic dysregulation, accelerating insulin resistance, dyslipidemia, oxidative stress, all which contribute increased burden cardiovascular PsA. This review explores intricate interplay between mediators—such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-17 (IL-17),—adipokine imbalances, lipid metabolism abnormalities, foster endothelial dysfunction atherosclerosis. The dysregulation adipokines, including leptin, adiponectin, resistin, further perpetuates cascades, exacerbating Additionally, alterations seen PsA, particularly resistance dysfunction, not only comorbidities but also impact severity therapeutic response. Understanding these mechanistic links imperative for refining risk stratification strategies tailoring interventions. By integrating targeted immunomodulatory therapies with management, more comprehensive approach PsA treatment can be achieved. Future research must focus on elucidating shared pathways, enabling development innovative mitigate both complications

Language: Английский

Citations

0
Impact of a High-Fat Diet on the Gut Microbiome: A Comprehensive Study of Microbial and Metabolite Shifts During Obesity DOI Creative Commons
Md Abdullah Al Mamun, Ahmed Rakib, Mousumi Mandal

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(6), P. 463 - 463

Published: March 20, 2025

Over the last few decades, prevalence of metabolic diseases such as obesity, diabetes, non-alcoholic fatty liver disease, hypertension, and hyperuricemia has surged, primarily due to high-fat diet (HFD). The pathologies these show disease-specific alterations in composition function their gut microbiome. How HFD alters microbiome its metabolite mediate adipose tissue (AT) inflammation obesity is not well known. Thus, this study aimed identify changes metabolomic signatures induced by an alter obesity. To explore microbiota metabolites, 16S rRNA gene amplicon sequencing analyses were performed after normal (ND) feeding. We noticed that, at taxonomic levels, number operational units (OTUs), along with Chao Shannon indexes, significantly shifted HFD-fed mice compared those fed a ND. Similarly, phylum level, increase Firmicutes decrease Bacteroidetes mice. At genus Lactobacillus Ruminococcus was observed, while Allobaculum, Clostridium, Akkermansia markedly reduced group. Many bacteria from impair bile acid metabolism restrict weight loss. are efficient breaking down complex carbohydrates into short-chain acids (SCFAs) other whereas involved more balanced or energy extraction. over enhances absorption calories food, which may contribute Taken together, altered metabolites trigger AT inflammation, contributes dysregulation disease progression. highlights potential development therapeutic strategies for related disorders.

Language: Английский

Citations

0
Life’s Crucial 9 and psoriasis: a mediation analysis of systemic inflammation response index using NHANES cohort data DOI Creative Commons
Xinyan Liu,

Qirui Deng,

Hongfeng Tang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 15, 2025

Background Psoriasis is a chronic, recurrent, inflammatory disease. The aim of this study was to investigate the association between Life’s Crucial 9 (LC9) score and risk psoriasis examine mediating role system inflammation response index (SIRI). Methods Utilizing data from National Health Nutrition Examination Survey (NHANES) spanning 2009 2014, employed multifactor logistic regression, restricted triple spline analysis, various subgroup analyses evaluate correlation LC9 scores occurrence psoriasis. Furthermore, mediation were executed SIRI’s possible intermediary effect in linkage Results This included 11,499 US adults with 345 patients. In fully adjusted models, notable inverse relationship identified prevalence (OR = 0.90, 95% CI: 0.80, 0.99). After adjusting for all covariates, no significant interactions found analyses. addition, analysis showed that SIRI mediated (mediation ratio: 7.02%, p 0.004). Conclusions Higher reduce And, by SIRI. suggests we should actively regulate our lifestyles improve cardiovascular health, thereby preventing delaying onset

Language: Английский

Citations

0
The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression DOI Creative Commons

Maria-Lorena Mustață,

Mihaela Ionescu,

Lucreţiu Radu

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(24), P. 2887 - 2887

Published: Dec. 23, 2024

Background/Objectives: Psoriasis is a chronic dermatological condition with systemic implications, especially metabolic syndrome (MS). This study evaluated the vicious cycle where obesity and MS exacerbate inflammation that complicates efficacy of psoriasis therapies by examining PASI score over one-year period. Patients were classified into two subgroups: those alone (PSO) both (PSO-MS). Methods: A total 150 patients, half whom also concomitantly presented syndrome, received biologic comprising anti-IL-17, anti-IL-23, anti-TNF-a, or methotrexate, scores assessed at baseline 3, 6, 12 months. Results: All treatments showed significant reductions in PASI; however, patients PSO more marked than PSO-MS group. Anti-IL-17 produced greatest sustained long-term improvements, whereas anti-IL-23 prompt early improvements. Increases BMI leptin concentrations associated modest rate reduction score, underlining impact dysfunction on treatment efficacy. Conclusions: highlights importance managing comorbidities such as psoriasis, interplay between health further therapeutic outcomes.

Language: Английский

Citations

1